Oral versus i.v. antibiotics for community-acquired pneumonia in children: A cost-minimisation analysis

European Respiratory Journal

Volumn 35, Issue 4, 2010, Pages 858-864

  Lorgelly, P K ^a   Atkinson, M ^b   Lakhanpaul, M ^e   Smyth, A R ^c   Vyas, H ^d   Weston, V ^d   Stephenson, T ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Cost minimisation analysis; Paediatric; Pneumonia; Treatment

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; PENICILLIN G;

ARTICLE; CHILD; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH SERVICE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SOCIETY; TREATMENT OUTCOME; UNITED KINGDOM;

ADMINISTRATION, ORAL; ADOLESCENT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CHILD; CHILD, HOSPITALIZED; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; COST SAVINGS; GREAT BRITAIN; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; PENICILLIN G; PNEUMONIA, BACTERIAL; STATE MEDICINE;

EID: 77951183403     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00087209     Document Type: Article

References (30)

1. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-837.
2. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997; 10: 1530-1534.
3. Bartolome M, Almirall J, Morera J, et al. A population-based study of the costs of care for community-acquired pneumonia. Eur Respir J 2004; 23: 610-616.
4. Goss CH, Rubenfeld GD, Park DR, et al. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital. Chest 2003; 124: 2148-2155.
5. Farha T, Thomson AH. The burden of pneumonia in children in the developed world. Paediatr Respir Rev 2005; 6: 76-82.
6. Shoham Y, Dagan R, Givon-Lavi N, et al. Community-acquired pneumonia in children: quantifying the burden on patients and their families including decrease in quality of life. Pediatrics 2005; 115: 1213-1219.
7. Li JZ, Winston LG, Moore DH, et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007; 120: 783-790.
8. Scalera NM, File TM Jr. How long should we treat community-acquired pneumonia? Curr Opin Infect Dis 2007; 20: 177-181.
9. Atkinson M, Lakhanpaul M, Smyth A, et al. Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial. Thorax 2007; 62: 1102-1106.
10. British Thoracic Society of Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in childhood. Thorax 2002; 57: i1-i24.
11. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001; 10: 179-184.
12. Royal College of Paediatricians and Child Health, Medicines for Children. London, Royal College of Paediatrics and Child Health and the Neonatal and Paediatric Pharmacists Group, 2001.
13. Netten A, Curtis L. Unit Costs of Health and Social Care 2002. Canterbury, PSSRU, University of Kent, 2002.
14. Salisbury C, Chalder M, Manku-Scott T, et al. The National Evaluation of NHS Walk-in Centres: Final Report. 2002. www.epi.bris.ac.uk/wic/pdf/ WIC%20Evaluation%20Report%20-%20Final.pdf Date last accessed: September 20, 2007. Date last updated: July 2, 2002.
15. The Comptroller and Auditor General. NHS Direct in England. HC 505 Session 2001-2002. 2002. London, The Stationery Office. www.nao.org.uk/ publications/nao-reports/01-02/0102505.pdf Date last accessed: September 20, 2007. Date last updated: January 2002.
16. British Medical Association and Royal Pharmaceutical Society of Great Britain, British National Formulary. London, BMJ, 2002.
17. The AA. Routeplanner (GB): Maps and directions. www.theaa.com/ travelwatch/planner-main.jsp?database5B Date last accessed: March 3, 2007. Date last updated: 2009.
18. The AA. Motoring costs. 2002. www.theaa.com/staticdocs/pdf/allaboutcars/ fuel/petrol2002.pdf Date last accessed: September 20, 2007. Date last updated: November 24, 2002.
19. Office for National Statistics. The New Earnings Survey. London, The Stationery Office, 2002.
20. Davison A, Hinkley D. Bootstrap Methods and their Application. Cambridge, Cambridge University Press, 1997.
21. Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 1994; 3: 95-104.
22. Clark JE, Hammal D, Spencer D, et al. Children with pneumonia: how do they present and how are they managed? Arch Dis Child 2007; 92: 394-398.
23. Curtis L. Unit Costs of Health and Social Care 2008. Canterbury, PSSRU, University of Kent, 2008.
24. Al Eidan FA, McElnay JC, Scott MG, et al. Use of a treatment protocol in the management of community-acquired lower respiratory tract infection. J Antimicrob Chemother 2000; 45: 387-394.
25. MacFaul R, Werneke U. Recent trends in hospital use by children in England. Arch Dis Child 2001; 85: 203-207.
26. Di Ciommo V, Russo P, Attanasio E, et al. Clinical and economic outcomes of pneumonia in children: a longitudinal observational study in an Italian paediatric hospital. J Eval Clin Pract 2002; 8: 341-348.
27. Opmeer BC, El Moussaoui R, Bossuyt PM, et al. Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia. J Antimicrob Chemother 2007; 60: 1131-1136.
28. Newby D, Hill S. Use of pharmacoeconomics in prescribing research. Part 2: cost-minimization analysis - when are two therapies equal? J Clin Pharm Ther 2003; 28: 145-150.
29. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
30. Horsman J, Furlong W, Feeny D, et al. The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003; 1: 54.